The University of Kentucky filed a lawsuit against the Lexington Herald-Leader newspaper to avoid revealing information on a failed deal between the university and a cardiology company, the Herald-Leader reports.

AstraZeneca announced on Oct. 4 that patients with symptomatic peripheral artery disease who took ticagrelor (Brilinta) did not have better outcomes than those who received clopidogrel, a rival blood thinner.

Accountable care organizations (ACOs) should play a major role for the cardiac care bundled payments model that the Centers for Medicare & Medicaid Services (CMS) proposed in July, according to the American Group Medical Association (AMGA).

Eight medical organizations, antitobacco groups and three pediatricians filed a federal lawsuit on Oct. 4 against the U.S. Food and Drug Administration (FDA). They want the agency to enforce The Tobacco Control Act and issue a final rule requiring graphic health warnings on cigarette packs and advertising.

For the second time in less than a month, Aralez Pharmaceuticals has struck a deal with a major pharmaceuticals company for a cardiovascular medication.

A new reimbursement model for cardiac care delivery could launch as early as July 1, 2017—giving cardiologists less than a year to prepare to practice in an environment with more risks and different opportunities. Get engaged now, say the experts. 

Amgen and Arrowhead Pharmaceuticals announced Sept. 29 that the companies had signed two agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease.

In 2015, the median compensation for cardiologists working in hospital integrated practices increased to $577,756, and the median compensation for cardiologists working in private groups increased to $486,777, according to a survey from MedAxiom.